On December 18, Zuoli Pharmaceutical announced that it had signed the “Deqing Hospital Takeover Agreement” with the Deqing County Health and Family Planning Bureau of Zhejiang Province (hereinafter referred to as Deqing County Health Planning Bureau), and Deqing County Health Bureau took over Deqing. In the hospital, Zuoli Pharmaceuticals has withdrawn from co-operation.

According to the agreement between the two parties, the 75% sponsorship of Deqing Hospital held by Zuoli Pharmaceutical was taken over by Deqing County Health and Welfare Bureau. As the consideration, the former will receive compensation of about 164 million yuan. After the completion of this transaction, Zuoli Pharmaceutical will completely withdraw from the cooperation medical treatment project of Deqing Hospital and no longer hold the rights of the organizers of Deqing Hospital.

The cooperation between Zuoli Pharmaceutical and Deqing County Health Bureau began three years ago. In April 2015, Zuoli Pharmaceutical and Deqing County Health and Welfare Bureau signed the “Framework Agreement on the Introduction of Social Capital to the Third People’s Hospital of Deqing County to Participate in the Cooperation and Management of Medical Treatment”. In October of the same year, the two sides signed the “Deqing County Third People’s Hospital Social Capital Participates in the Cooperative Medical Agreement (hereinafter referred to as the “Cooperative Medical Agreement”). According to the data at the time, Zuoli Pharmaceutical and the Deqing County Health and Welfare Bureau cooperated to set up a newly established hospital to be registered as Deqing Hospital. Among them, Zuoli Pharmaceuticals invested 189 million yuan in cash, accounting for the total amount of funds opened by Deqing Hospital. 75%, and gradually implement the contribution of the start-up funds in three years.

As of October 31, 2018, the total amount of funds invested by Zuoli Pharmaceutical in Deqing Hospital was approximately 144 million yuan, which was mainly used for the construction of the new hospital in Deqing Hospital. However, since October 31, 2018, Zuoli Pharmaceutical will no longer invest other funds in Deqing Hospital.

According to the analysis of the announcement, with the continuous deepening of the medical system reform, Zuoli Pharmaceuticals has withdrawn from Deqing Hospital to cooperate in the operation of medical treatment, which is conducive to the construction and development of medical associations, medical communities and regional centers led by public hospitals in Deqing County. Local medical environment and meeting medical needs. However, the more important reason may be to optimize the development strategy of the company and return to the consideration of the pharmaceutical manufacturing industry.

Founded in 2000, Zuoli Pharmaceutical Co., Ltd. is a pharmaceutical company in Zhejiang Province. It is based on the bio-fermentation technology of medicinal fungi to produce traditional Chinese medicine products. At present, it is mainly engaged in the research, development, production and sales of medicinal fungi series products, traditional Chinese medicine decoction pieces and traditional Chinese medicine formula granules. However, with the promotion of the “new medical reform” in 2009, the policy encourages and supports the multi-medical pattern. Many traditional pharmaceutical companies have begun to transform themselves into hospitals and other medical institutions, and Zuoli Pharmaceutical is one of them.

Since 2014, Zuoli Pharmaceutical has opened the road of “buy, buy and buy” business expansion: In 2014, Zuoli Pharmaceutical acquired 51% equity of Qinghai Everest and 65% equity of Kaixin Pharmaceutical, integrating medical marketing channels; In 2015, through the increase of the capital of Deqing Sanyuan, it was involved in the medical service field. In addition, Zuoli Pharmaceutical also established a health industry investment platform to form an industrial chain layout spanning pharmaceutical manufacturing, pharmaceutical circulation and medical services. However, the big network around “slow disease and health management” has not brought synergy to the company.

In November 2017, Zuoli Pharmaceutical and Hangzhou Tongxie signed the "Equity Transfer Agreement", which first reduced the registered capital of Kaixin Pharmaceutical from 15 million yuan to 10 million yuan. After the capital reduction is completed, it will hold the 85% of Kaixin Pharmaceutical's equity was transferred to Hangzhou Tongxie and began to “poor assets”. Part of the reason for the withdrawal of Deqing Hospital's cooperation in medical treatment is that its profit is facing difficulties. According to the announcement, in 2017, Deqing Hospital's business income was 144 million yuan, and in 2018 this figure was 107 million yuan.

After the withdrawal of cooperation in medical treatment, Zuoli Pharmaceutical will turn to focus on the main business of medicinal fungus Wuling series and Bailing tablets, traditional Chinese medicine decoction pieces and formula granules. However, in recent years, investment mergers and acquisitions still have "one chicken feathers" to be processed. In the first half of 2018, Zuoli Pharmaceuticals' revenue was 392 million yuan, down 11.24% from the same period of the previous year; total profit was 43.6969 million yuan, down 30.27% over the same period of last year; attributable to listed companies The net profit of shareholders was 34.507 million yuan, a decrease of 28.40% over the same period of the previous year. These downturns are obviously not remedy for the investment income of 2001.36 million yuan obtained from this transaction.

Zuoli Pharmaceuticals is not the only pharmaceutical company that has divested its hospital business. In October of this year, China Resources Sanjiu issued an announcement saying that it intends to transfer 82.89% of the shares of Sanjiu Hospital held by the state-owned property rights exchange in accordance with the listing procedure of the state-owned property rights exchange, and return to the main business. Although the policy dividends of social medical treatment still exist, for traditional pharmaceutical companies, how to think about their own positioning and layout may be a more pressing issue.

DNA/RNA Purification Kit

The RNA purification kit is used to purify and recover RNA molecules transcribed in vitro and total RNA extracted from various materials, which can effectively remove contaminating impurities in RNA samples. The recovery rate of this product can reach 80%, and the OD260/OD280 ratio of the obtained RNA is generally about 2.0, which can be directly used in subsequent sensitive experiments (such as microarray analysis, fluorescence RT-PCR, etc.). With the deepening of transcriptomics, the complexity of RNA types, expression regulation and functions is far beyond our imagination.

Removing ribosomal RNAs that account for more than 80% helps to focus sequencing on less abundant but informative RNAs. At present, the removal of rRNA is mainly through the combined use of probe and RNase H. The processed RNA will be mixed with many digestion products, enzymes and ions, which is not conducive to the subsequent construction of RNA library. Take the Columnar RNA Purification Kit as an example. Trizol is a ready-to-use reagent that can be used to purify total RNA from tissues and cells. This is a single-phase solution of phenol and guanidine isothiocyanate that facilitates lysis of tissues and cells, inhibiting RNases to maintain RNA integrity.

Covid-19 Nucleic Acid Extraction Reagent,Nucleic Acid Extraction Reagent Kits,Dna Purification Kit,Rna Purification Kit

Jilin Sinoscience Technology Co. LTD , https://www.jilinsinoscience.com